$LUMO
Lumos Pharma Inc

2018 Q1 Form 10-K Financial Statement

#000112623418000026 Filed on March 05, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2016 Q4 2016 Q3
Revenue $9.900M $12.70M $15.35M
YoY Change 258.57% 66.01% 7.99%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.300M $7.200M $7.700M
YoY Change 1.22% -6.49% 4.05%
% of Gross Profit
Research & Development $20.31M $20.20M $24.46M
YoY Change 29.18% 36.49% 8.69%
% of Gross Profit
Depreciation & Amortization $334.0K $600.0K $300.0K
YoY Change -7.22% 20.0% -40.0%
% of Gross Profit
Operating Expenses $28.61M $27.40M $32.21M
YoY Change 19.4% 21.78% 7.76%
Operating Profit -$18.71M -$13.97M -$16.69M
YoY Change -11.76% -5.77% 6.4%
Interest Expense $13.00K $100.0K $5.000K
YoY Change -87.74% -94.32%
% of Operating Profit
Other Income/Expense, Net $396.0K $100.0K $19.00K
YoY Change -1684.0% -130.16%
Pretax Income -$18.31M -$13.80M -$16.85M
YoY Change -13.73% -6.76% 7.0%
Income Tax $0.00 -$640.0K -$1.308M
% Of Pretax Income
Net Earnings -$18.31M -$13.51M -$15.54M
YoY Change -12.45% -37.4% -2.3%
Net Earnings / Revenue -184.95% -106.32% -101.27%
Basic Earnings Per Share -$0.49 -$0.46 -$0.54
Diluted Earnings Per Share -$4.463M -$0.46 -$0.54
COMMON SHARES
Basic Shares Outstanding 37.16M shares 29.13M shares 28.98M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2016 Q4 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $143.9M $131.5M $148.3M
YoY Change 21.74% -33.52% -26.0%
Cash & Equivalents $143.9M $131.5M $148.3M
Short-Term Investments $0.00 $0.00
Other Short-Term Assets $5.600M $5.900M $10.70M
YoY Change -37.78% 18.0% 494.44%
Inventory
Prepaid Expenses $5.762M $5.921M $10.69M
Receivables
Other Receivables $10.68M $24.53M
Total Short-Term Assets $160.2M $167.9M $179.2M
YoY Change 11.91% -19.33% -17.51%
LONG-TERM ASSETS
Property, Plant & Equipment $4.700M $6.835M $7.188M
YoY Change -27.31% -34.28% -25.34%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $20.54M $6.835M $7.188M
YoY Change 217.65% -34.28% -25.34%
TOTAL ASSETS
Total Short-Term Assets $160.2M $167.9M $179.2M
Total Long-Term Assets $20.54M $6.835M $7.188M
Total Assets $180.7M $174.7M $186.3M
YoY Change 20.8% -20.04% -17.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.300M $22.88M $2.367M
YoY Change -44.89% 525.05% 58.43%
Accrued Expenses $14.50M $14.31M $37.26M
YoY Change -18.56% 63.33% 356.89%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $100.0K $200.0K $200.0K
YoY Change -50.0% -64.16% -64.16%
Total Short-Term Liabilities $20.00M $37.91M $40.65M
YoY Change -28.5% 155.42% 262.42%
LONG-TERM LIABILITIES
Long-Term Debt $100.0K $300.0K $300.0K
YoY Change -50.0% -18.48% -26.65%
Other Long-Term Liabilities $7.000M $7.100M $7.100M
YoY Change -1.41% -6.58% -8.97%
Total Long-Term Liabilities $7.100M $7.376M $7.422M
YoY Change -2.7% -6.96% -9.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.00M $37.91M $40.65M
Total Long-Term Liabilities $7.100M $7.376M $7.422M
Total Liabilities $27.10M $45.28M $48.07M
YoY Change -23.16% 98.88% 147.68%
SHAREHOLDERS EQUITY
Retained Earnings -$237.4M -$165.5M -$152.0M
YoY Change 27.36% 105.98% 158.6%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $853.0K $784.0K
YoY Change 10.64% 42.29%
Treasury Stock Shares 30.05K shares 25.23K shares
Shareholders Equity $138.0M $129.5M $138.3M
YoY Change
Total Liabilities & Shareholders Equity $180.7M $174.7M $186.3M
YoY Change 20.8% -20.04% -17.84%

Cashflow Statement

Concept 2018 Q1 2016 Q4 2016 Q3
OPERATING ACTIVITIES
Net Income -$18.31M -$13.51M -$15.54M
YoY Change -12.45% -37.4% -2.3%
Depreciation, Depletion And Amortization $334.0K $600.0K $300.0K
YoY Change -7.22% 20.0% -40.0%
Cash From Operating Activities -$14.68M -$17.00M -$13.20M
YoY Change 12.81% 102.38% 88.57%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$100.0K -$100.0K
YoY Change -100.0% -80.0% -92.31%
Acquisitions
YoY Change
Other Investing Activities $100.0K $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities $83.00K -$200.0K -$100.0K
YoY Change -738.46% -140.0% -66.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $155.0K
YoY Change -10.92%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$224.0K 400.0K 1.100M
YoY Change -1.75% -93.75% 10.0%
NET CHANGE
Cash From Operating Activities -$14.68M -17.00M -13.20M
Cash From Investing Activities $83.00K -200.0K -100.0K
Cash From Financing Activities -$224.0K 400.0K 1.100M
Net Change In Cash -$14.82M -16.80M -12.20M
YoY Change 11.83% 1020.0% 93.65%
FREE CASH FLOW
Cash From Operating Activities -$14.68M -$17.00M -$13.20M
Capital Expenditures $0.00 -$100.0K -$100.0K
Free Cash Flow -$14.68M -$16.90M -$13.10M
YoY Change 12.51% 113.92% 129.82%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
27218000 USD
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
CY2017 dei Document Type
DocumentType
10-K
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0001126234
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37155838 shares
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2017Q2 dei Entity Public Float
EntityPublicFloat
159637289 USD
CY2017 dei Entity Registrant Name
EntityRegistrantName
NEWLINK GENETICS CORP
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2014 nlnk Collaborative Arrangement Numberof Arrangements
CollaborativeArrangementNumberofArrangements
2 arrangement
CY2017 nlnk Common Stock Voting Rights Votesper Share
CommonStockVotingRightsVotesperShare
1 shares
CY2016Q4 nlnk Deferred Government Grants Obligations Noncurrent
DeferredGovernmentGrantsObligationsNoncurrent
6000000 USD
CY2017Q4 nlnk Deferred Government Grants Obligations Noncurrent
DeferredGovernmentGrantsObligationsNoncurrent
6000000 USD
CY2016Q2 nlnk Effective Income Tax Rate Reconciliation Sharebased Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount
127000 USD
CY2016Q3 nlnk Effective Income Tax Rate Reconciliation Sharebased Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount
513000 USD
CY2015 nlnk Increase Decrease In State Research And Development Credit Receivable
IncreaseDecreaseInStateResearchAndDevelopmentCreditReceivable
-13000 USD
CY2016 nlnk Increase Decrease In State Research And Development Credit Receivable
IncreaseDecreaseInStateResearchAndDevelopmentCreditReceivable
0 USD
CY2017 nlnk Increase Decrease In State Research And Development Credit Receivable
IncreaseDecreaseInStateResearchAndDevelopmentCreditReceivable
0 USD
CY2015 nlnk Potential Milestone Expense
PotentialMilestoneExpense
2000000 USD
CY2016 nlnk Potential Milestone Expense
PotentialMilestoneExpense
2000000 USD
CY2017 nlnk Potential Milestone Expense
PotentialMilestoneExpense
1400000 USD
CY2017Q4 nlnk Sharebased Compensation Arrangementby Sharebased Payment Award Options Outstanding Intrinsic Value Per Share
SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare
8.11
CY2017 nlnk Tax Cutsand Jobs Actof2017 Income Tax Expense Benefit
TaxCutsandJobsActof2017IncomeTaxExpenseBenefit
-140000 USD
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
22883000 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9256000 USD
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14309000 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12467000 USD
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5726000 USD
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6638000 USD
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
295535000 USD
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
389786000 USD
CY2015 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
6100000 USD
CY2015 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
561000 USD
CY2016 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
82000 USD
CY2017 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
289000 USD
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15940000 USD
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16707000 USD
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18508000 USD
CY2015 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
54000 USD
CY2016 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
0 USD
CY2017 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
561000 USD
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15900000 USD
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16700000 USD
CY2016 us-gaap Asset Impairment Charges
AssetImpairmentCharges
3958000 USD
CY2017 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2016Q4 us-gaap Assets
Assets
174747000 USD
CY2017Q4 us-gaap Assets
Assets
180697000 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
167912000 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
175466000 USD
CY2017Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
5231000 USD
CY2015 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
398000 USD
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
CY2016Q4 us-gaap Capital Leased Assets Gross
CapitalLeasedAssetsGross
801000 USD
CY2017Q4 us-gaap Capital Leased Assets Gross
CapitalLeasedAssetsGross
801000 USD
CY2016Q4 us-gaap Capital Leases Balance Sheet Assets By Major Class Net
CapitalLeasesBalanceSheetAssetsByMajorClassNet
215000 USD
CY2017Q4 us-gaap Capital Leases Balance Sheet Assets By Major Class Net
CapitalLeasesBalanceSheetAssetsByMajorClassNet
149000 USD
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
74000 USD
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
1000 USD
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
73000 USD
CY2016Q4 us-gaap Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
586000 USD
CY2017Q4 us-gaap Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
652000 USD
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18500000 USD
CY2015 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
190404000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
195620000 USD
CY2016Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
6835000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
131490000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
158708000 USD
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5216000 USD
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-64130000 USD
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-15469000 USD
CY2015 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
9622000 USD
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29193718 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37168122 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29163673 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37109556 shares
CY2016Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
292000 USD
CY2017Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
372000 USD
CY2015 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
5522000 USD
CY2016 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-6469000 USD
CY2017 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-332000 USD
CY2015 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
6738000 USD
CY2016 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-5356000 USD
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-419000 USD
CY2015 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1216000 USD
CY2016 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1113000 USD
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-87000 USD
CY2015 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 USD
CY2016 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 USD
CY2017 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-140000 USD
CY2015 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2016 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-140000 USD
CY2016Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
1200000 USD
CY2017Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
1100000 USD
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
90000 USD
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
92000 USD
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1091000 USD
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
998000 USD
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
391000 USD
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
56000 USD
CY2015 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 USD
CY2016 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 USD
CY2017 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 USD
CY2016Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
13000 USD
CY2017Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
39000 USD
CY2016Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
163000 USD
CY2017Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
17000 USD
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
35122000 USD
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
50198000 USD
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
654000 USD
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
10622000 USD
CY2016Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
552000 USD
CY2017Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
297000 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
143000 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
0 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
20836000 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
26327000 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
491000 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
327000 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
427000 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
789000 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
11843000 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
11780000 USD
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
35122000 USD
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
35100000 USD
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
50198000 USD
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
50200000 USD
CY2015 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
361000 USD
CY2016 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
482000 USD
CY2017 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
361000 USD
CY2015 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
319000 USD
CY2016 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
446000 USD
CY2017 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
401000 USD
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1592000 USD
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2084000 USD
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1407000 USD
CY2016Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.82
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.12
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
CY2016Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2017Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
CY2017Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2017Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.41
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.94
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.30
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.2000
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0592
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0077
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3500
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3500
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3500
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.1370
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.1207
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2410
CY2015 us-gaap Effective Income Tax Rate Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary
EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
-0.4360
CY2016 us-gaap Effective Income Tax Rate Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary
EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
-0.1588
CY2017 us-gaap Effective Income Tax Rate Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary
EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
-0.0736
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0050
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0025
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0280
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0050
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0088
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0003
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.0230
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0000
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
18000000 USD
CY2015 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
7800000 USD
CY2016 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
13700000 USD
CY2017 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
16600000 USD
CY2015 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
6100000 USD
CY2016 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
0 USD
CY2017 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
0 USD
CY2017 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.00
CY2015 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
0 USD
CY2016 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
231000 USD
CY2017 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
0 USD
CY2015 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
5522000 USD
CY2016 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
-6469000 USD
CY2017 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
-472000 USD
CY2015 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
CY2016 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
CY2017 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-126000 USD
CY2015 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2016 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
397000 USD
CY2017 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
30689000 USD
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
33226000 USD
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
31726000 USD
CY2016Q4 us-gaap Government Contract Receivable
GovernmentContractReceivable
23900000 USD
CY2017Q4 us-gaap Government Contract Receivable
GovernmentContractReceivable
9300000 USD
CY2016Q4 us-gaap Government Contract Receivable Unbilled Amounts
GovernmentContractReceivableUnbilledAmounts
4300000 USD
CY2017Q4 us-gaap Government Contract Receivable Unbilled Amounts
GovernmentContractReceivableUnbilledAmounts
465000 USD
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-33643000 USD
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-90511000 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-72510000 USD
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6738000 USD
CY2016Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-640000 USD
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5356000 USD
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-559000 USD
CY2015 us-gaap Income Taxes Paid
IncomeTaxesPaid
4814000 USD
CY2016 us-gaap Income Taxes Paid
IncomeTaxesPaid
1022000 USD
CY2017 us-gaap Income Taxes Paid
IncomeTaxesPaid
643000 USD
CY2016Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
5975000 USD
CY2017Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
356000 USD
CY2016Q4 us-gaap Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
0 USD
CY2017Q4 us-gaap Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
140000 USD
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
245000 USD
CY2016 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
24770000 USD
CY2016 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-6834000 USD
CY2015 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
73000 USD
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-12752000 USD
CY2017 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
5479000 USD
CY2016 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
908000 USD
CY2017 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
91000 USD
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-68000 USD
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-335000 USD
CY2015 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
1672000 USD
CY2016 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
19139000 USD
CY2017 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-14350000 USD
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3379000 USD
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
965000 USD
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
305000 USD
CY2015 us-gaap Interest Expense
InterestExpense
105000 USD
CY2016 us-gaap Interest Expense
InterestExpense
22000 USD
CY2017 us-gaap Interest Expense
InterestExpense
119000 USD
CY2015 us-gaap Interest Paid
InterestPaid
105000 USD
CY2016 us-gaap Interest Paid
InterestPaid
22000 USD
CY2017 us-gaap Interest Paid
InterestPaid
15000 USD
CY2015 us-gaap Investment Income Interest
InvestmentIncomeInterest
78000 USD
CY2016 us-gaap Investment Income Interest
InvestmentIncomeInterest
237000 USD
CY2017 us-gaap Investment Income Interest
InvestmentIncomeInterest
616000 USD
CY2016Q4 us-gaap Liabilities
Liabilities
45281000 USD
CY2017Q4 us-gaap Liabilities
Liabilities
29140000 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
174747000 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
180697000 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
37905000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22031000 USD
CY2016Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
7376000 USD
CY2017Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
7109000 USD
CY2015 us-gaap Licenses Revenue
LicensesRevenue
36143000 USD
CY2016 us-gaap Licenses Revenue
LicensesRevenue
3526000 USD
CY2017 us-gaap Licenses Revenue
LicensesRevenue
390000 USD
CY2016Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
285000 USD
CY2017Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
111000 USD
CY2016Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
232000 USD
CY2017Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
160000 USD
CY2016Q4 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
517000 USD
CY2017Q4 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
271000 USD
CY2015 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23085000 USD
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1883000 USD
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
75288000 USD
CY2015 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
6218000 USD
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-66000 USD
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
211000 USD
CY2015 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24087000 USD
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-65947000 USD
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-48281000 USD
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-40381000 USD
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-23720000 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-32389000 USD
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-15540000 USD
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-85155000 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-20913000 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-16726000 USD
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-20626000 USD
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-13506000 USD
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-13686000 USD
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-71951000 USD
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-41000 USD
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
247000 USD
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
371000 USD
CY2015 us-gaap Operating Expenses
OperatingExpenses
102103000 USD
CY2016 us-gaap Operating Expenses
OperatingExpenses
126526000 USD
CY2017 us-gaap Operating Expenses
OperatingExpenses
101592000 USD
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-33602000 USD
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-25393000 USD
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-34528000 USD
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-16687000 USD
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-13970000 USD
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-90758000 USD
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-21198000 USD
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-16727000 USD
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-20905000 USD
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-14051000 USD
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-72881000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
12660000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1157000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1008000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1104000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
9391000 USD
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1700000 USD
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1700000 USD
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1200000 USD
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14000 USD
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
32000 USD
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-126000 USD
CY2016Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
24526000 USD
CY2017Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
10176000 USD
CY2015 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
561000 USD
CY2016 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
82000 USD
CY2017 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
289000 USD
CY2017 us-gaap Payments For Restructuring
PaymentsForRestructuring
1570000 USD
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3995000 USD
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2246000 USD
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
43000 USD
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6226000 USD
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2017Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5921000 USD
CY2015 us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
13796000 USD
CY2016 us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
197000 USD
CY2017 us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
6651000 USD
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13534000 USD
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
74416000 USD
CY2015 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
4206000 USD
CY2016 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2222000 USD
CY2017 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1407000 USD
CY2015 us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
10213000 USD
CY2016 us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
2180000 USD
CY2017 us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
0 USD
CY2015 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
CY2016 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
CY2017 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
254000 USD
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12561000 USD
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11729000 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6835000 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5091000 USD
CY2015 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
194000 USD
CY2016 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
257000 USD
CY2017 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
246000 USD
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
71414000 USD
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
93300000 USD
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
69866000 USD
CY2017Q3 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.50
CY2016 us-gaap Restructuring Charges
RestructuringCharges
11600000 USD
CY2017 us-gaap Restructuring Charges
RestructuringCharges
1700000 USD
CY2017 us-gaap Restructuring Charges
RestructuringCharges
1735000 USD
CY2016Q4 us-gaap Restructuring Reserve
RestructuringReserve
42000 USD
CY2017Q4 us-gaap Restructuring Reserve
RestructuringReserve
207000 USD
CY2017 us-gaap Restructuring Reserve Accrual Adjustment1
RestructuringReserveAccrualAdjustment1
0 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-165508000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-237459000 USD
CY2015 us-gaap Revenue From Grants
RevenueFromGrants
32400000 USD
CY2015 us-gaap Revenue From Grants
RevenueFromGrants
32358000 USD
CY2016 us-gaap Revenue From Grants
RevenueFromGrants
32242000 USD
CY2016 us-gaap Revenue From Grants
RevenueFromGrants
32200000 USD
CY2017 us-gaap Revenue From Grants
RevenueFromGrants
28321000 USD
CY2017 us-gaap Revenue From Grants
RevenueFromGrants
28300000 USD
CY2016Q4 us-gaap Revenues
Revenues
12703000 USD
CY2016Q1 us-gaap Revenues
Revenues
5708000 USD
CY2016Q2 us-gaap Revenues
Revenues
2012000 USD
CY2015 us-gaap Revenues
Revenues
68500000 USD
CY2016Q3 us-gaap Revenues
Revenues
15345000 USD
CY2016 us-gaap Revenues
Revenues
35800000 USD
CY2017Q1 us-gaap Revenues
Revenues
2761000 USD
CY2017Q2 us-gaap Revenues
Revenues
10370000 USD
CY2017Q3 us-gaap Revenues
Revenues
5482000 USD
CY2017Q4 us-gaap Revenues
Revenues
10098000 USD
CY2017 us-gaap Revenues
Revenues
28700000 USD
CY2015 us-gaap Sales Revenue Net
SalesRevenueNet
68501000 USD
CY2016 us-gaap Sales Revenue Net
SalesRevenueNet
35768000 USD
CY2017 us-gaap Sales Revenue Net
SalesRevenueNet
28711000 USD
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
15940000 USD
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
16707000 USD
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
18508000 USD
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
2800000 USD
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P36M
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11600000 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
6000 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
11600000 USD
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
0.25
CY2015 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
1216000 USD
CY2016 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
1113000 USD
CY2017 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
-87000 USD
CY2015 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
851000 USD
CY2016 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
543000 USD
CY2017 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
445000 USD
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13534000 USD
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
19333000 USD
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3355000 USD
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1679000 USD
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
962000 USD
CY2015 us-gaap Stock Issued During Period Value Treasury Stock Reissued
StockIssuedDuringPeriodValueTreasuryStockReissued
0 USD
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
196936000 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
195774000 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
129466000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
151557000 USD
CY2016 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
4000000 USD
CY2016Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
30045 shares
CY2017Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
58566 shares
CY2016Q4 us-gaap Treasury Stock Value
TreasuryStockValue
853000 USD
CY2017Q4 us-gaap Treasury Stock Value
TreasuryStockValue
1142000 USD
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
653000 USD
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
653000 USD
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
653000 USD
CY2017 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
0 USD
CY2015Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
CY2016Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
CY2017Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
335000 USD
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
0 USD
CY2017 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0 USD
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
14400000 USD
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
15100000 USD
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28586585 shares
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28979327 shares
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31304309 shares
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company&#8217;s cash and cash equivalents balance exceeds the federally insured limits. To limit the credit risk, the Company invests its excess cash primarily in high quality securities such as money market funds. </font></div></div>
CY2017 us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Business Activities</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:16px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NewLink Genetics Corporation (NewLink) was incorporated as a Delaware corporation on June&#160;4, 1999 and initiated operations in April of 2000.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NewLink and its subsidiaries (the Company) are devoting substantially all of their efforts toward research and development. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has incurred significant losses in all years since being incorporated, except for the year ended December 31, 2014, and has never generated revenue from commercial sales of its drugs. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying financial statements as of and for the year ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> have been prepared assuming the Company will continue as a going concern. The Company raised net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$37.6 million</font><font style="font-family:inherit;font-size:10pt;"> from its IPO, completed a follow-on offering of its common stock raising net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$49.0 million</font><font style="font-family:inherit;font-size:10pt;">, and raised an additional </font><font style="font-family:inherit;font-size:10pt;">$58.7 million</font><font style="font-family:inherit;font-size:10pt;"> in net proceeds from an at the market offering prior to March 31, 2015. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 29, 2016, the Company entered into a sales agreement with Cantor Fitzgerald &amp; Co., under which the Company may sell up to&#160;</font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;">&#160;in shares of its common stock in one or more placements at prevailing market prices for its common stock (the ATM Offering). As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company has raised net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$19.3 million</font><font style="font-family:inherit;font-size:10pt;"> from the ATM Offering. On October 6, 2017, the Company raised proceeds of </font><font style="font-family:inherit;font-size:10pt;">$55.2 million</font><font style="font-family:inherit;font-size:10pt;">, net of offering costs of </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;">, from the issuance of </font><font style="font-family:inherit;font-size:10pt;">5,750,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock in a public offering. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> license and collaboration agreements the Company entered into during 2014, the Company received a nonrefundable upfront cash payment of </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Genentech Inc., a member of the Roche Group, or Genentech, in 2014, and a nonrefundable upfront cash payment of </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Merck, Sharpe and Dohme Corp., or Merck, in 2014, as well as an additional milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Merck in February 2015. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's cash and cash equivalents after these agreements and offerings are expected to be adequate to satisfy the Company's liquidity requirements through 2019. If available liquidity becomes insufficient to meet the Company&#8217;s operating obligations as they come due, the Company's plans include pursuing alternative funding arrangements and/or reducing expenditures as necessary to meet the Company&#8217;s cash requirements. However, there is no assurance that, if required, the Company will be able to raise additional capital or reduce discretionary spending to provide the required liquidity. Failure by the Company to successfully execute its plans or otherwise address its liquidity needs may have a material adverse effect on its business and financial position, and may materially affect the Company&#8217;s ability to continue as a going concern.</font></div></div>
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles, or U.S.&#160;GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name View Source Status
0001126234-18-000026-index-headers.html Edgar Link pending
0001126234-18-000026-index.html Edgar Link pending
0001126234-18-000026.txt Edgar Link pending
0001126234-18-000026-xbrl.zip Edgar Link pending
chart-d653ff6c8c6858a18a8a03.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
newlogoa16.jpg Edgar Link pending
nlnk-20171231.xml Edgar Link completed
nlnk-20171231.xsd Edgar Link pending
nlnk-20171231x10k.htm Edgar Link pending
nlnk-20171231xex10481.htm Edgar Link pending
nlnk-20171231xex1061.htm Edgar Link pending
nlnk-20171231xex211.htm Edgar Link pending
nlnk-20171231xex231.htm Edgar Link pending
nlnk-20171231xex311.htm Edgar Link pending
nlnk-20171231xex312.htm Edgar Link pending
nlnk-20171231xex321.htm Edgar Link pending
nlnk-20171231_cal.xml Edgar Link unprocessable
nlnk-20171231_def.xml Edgar Link unprocessable
nlnk-20171231_lab.xml Edgar Link unprocessable
nlnk-20171231_pre.xml Edgar Link unprocessable
nlnkidotdppathwaya01.jpg Edgar Link pending
phaclogoimage1.gif Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending